Novartis to Discontinue CIRRUS-1 Study of CFZ533 (iscalimab) in Kidney Transplant Patients
Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies
Shots:
- The discontinuation is based on the interim analysis of data from the CIRRUS-1 study demonstrating that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant
- In the study, both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy, mycophenolate and corticosteroids)
- The company will continue the study of CFZ533 in liver transplant as the studies are exploring the potential treatment in other conditions, such as hidradenitis suppurativa and Sjögren’s syndrome
Click here to read full press release/ article | Ref: Novartis | Image: BioProcess International